Ontology highlight
ABSTRACT:
SUBMITTER: Kohler M
PROVIDER: S-EPMC4353284 | biostudies-literature | 2015 Feb
REPOSITORIES: biostudies-literature
Köhler Michael M Haag Susanne S Biester Katharina K Brockhaus Anne Catharina AC McGauran Natalie N Grouven Ulrich U Kölsch Heike H Seay Ulrike U Hörn Helmut H Moritz Gregor G Staeck Kerstin K Wieseler Beate B
BMJ (Clinical research ed.) 20150226
<h4>Background</h4>When a new drug becomes available, patients and doctors require information on its benefits and harms. In 2011, Germany introduced the early benefit assessment of new drugs through the act on the reform of the market for medicinal products (AMNOG). At market entry, the pharmaceutical company responsible must submit a standardised dossier containing all available evidence of the drug's added benefit over an appropriate comparator treatment. The added benefit is mainly determine ...[more]